Comparative Pharmacology
Head-to-head clinical analysis: AXERT versus ZOMIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXERT versus ZOMIG.
AXERT vs ZOMIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial blood vessels and inhibits trigeminal nerve activation and release of vasoactive neuropeptides.
Selective 5-HT1B/1D receptor agonist; constricts cranial blood vessels and inhibits trigeminal nerve transmission.
AXERT (almotriptan malate) is administered orally. The recommended adult dose is 6.25 mg or 12.5 mg as a single tablet. If headache recurs, the dose may be repeated after 2 hours, with a maximum of 2 doses per 24-hour period (not exceeding 25 mg per day).
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed, maximum 10 mg in 24 hours. Also available as 5 mg nasal spray and 3 mg subcutaneous injection.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 20-30 hours), supporting once-daily dosing for sustained antimigraine effect.
Mean terminal elimination half-life is approximately 3 hours (range 2.5-4 hours). In patients with hepatic impairment, half-life may be prolonged (up to 7 hours).
Approximately 57% of a dose is excreted in urine (10-15% unchanged, remainder as metabolites) and 38% in feces (primarily as metabolites) via biliary elimination.
Primarily hepatic metabolism via CYP1A2; approximately 10-15% excreted unchanged in urine, with the remainder eliminated as metabolites (mostly N-desmethylzolmitriptan and indoleacetic acid) in urine (60%) and feces (30%).
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine